|
|
|
NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
1.00 AMA PRA Category 1 Credits™
Learning Objective
To discuss the implications of the ACTIVE-A trial on clinical management regarding the use of combination antiplatelet therapy for stroke reduction in patients with atrial fibrillation (AF).
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Faculty and Editorial Board
Written By:
James A. Reiffel, MD, (Read Bio), Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons, New York, New York
Edited By:
Monica Zangwill, MD, MPH
Financial Disclosure Statement(s)
Dr Reiffel receives grants from sanofi-aventis US; Boehringer Ingelheim Corporation; GlaxoSmithKline; and Johnson & Johnson; is a consultant for GlaxoSmithKline; sanofi aventis US; Astellas Pharma Inc.; Xention Discovery Ltd., CV Therapeutics, Inc.; and LifeWatch Corp.; and receives honoraria from GlaxoSmithKline; sanofi-aventis US; Astellas Pharma Inc.; and Reliant Pharmaceuticals, Inc.
The content collaborators at Academy for Healthcare Education, Inc., have no financial relationships to disclose.
Dr Zangwill has no financial relationships to disclose.
Education Partner:
Academy for Healthcare Education
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|
